Jasper Therapeutics Inc (JSPR) — Institutional Investor Activity (Q2 2026)

JSPR ranks #6335 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

47 institutions disclose a position in JSPR, but none treat it as a major bet — even Lion Point Capital, LP, its most concentrated holder, allocates just 0.9% of its own portfolio to it.

Velan Capital Investment Management LP has trimmed its JSPR position for two straight quarters, cutting it by $3.8M while still holding $1.1M.

JSPR reported a net loss of $75.8M in its latest fiscal year.

• Not yet profitable — net loss of $75.8M in the latest fiscal year
• Net income declined year over year, from -$71.3M to -$75.8M
• Operating cash flow was negative, using $77.2M in cash
• Current ratio of 2.62x — enough short-term assets to cover short-term liabilities
• Liabilities run 7.62x equity — a highly leveraged balance sheet worth noting